Vertex Pharmaceuticals Incorporated (VRTX) Stock

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorporated is led by CEO Reshma Kewalramani, employs 6,100 people, headquartered in Boston, US, publicly traded since 1991.

Vertex Pharmaceuticals Incorporated (VRTX) stock trades at $483.33 with a market capitalization of $122.67B. The stock is valued at a price-to-earnings (P/E) ratio of 25.54, price-to-book of 5.64, price-to-sales of 9.39. Over the past 52 weeks the stock has ranged between $362.50 and $529.68, and currently trades 8.8% below its 52-week high.

On profitability, Vertex Pharmaceuticals Incorporated generates a return on equity (ROE) of 24.20% — well above the market average, a sign of a high-quality business, return on capital employed of 25.51%, an operating margin of 39.43%, a net profit margin of 35.40%.

In its most recent fiscal year, Vertex Pharmaceuticals Incorporated reported annual revenue of $12.1B, net profit of $4.0B, revenue has compounded at 14.2% a year over the last five years, profit at 7.8% a year.

The balance sheet shows a debt-to-equity ratio of 0.10 — a conservative balance sheet with little leverage risk, a current ratio of 2.90, total assets of $26.1B, $5.1B in cash and equivalents.

VRTX has an average daily trading volume of 1,540,431 shares, a beta of 0.31 (less volatile than the overall market).

Official website: www.vrtx.com